CA9 and neoplasm: Despite the significant and preferential tumor accumulation of the anti-CAIX mAb, a preliminary analysis of tumor volume growth indicated a negligible anticancer activity of ISAC 3 (data not shown), in agreement with the low amount of free payload detected in the tumor.